NYSE:QGENLife Sciences
Should Qiagen’s Expanded QIAcuity Automation Push Reshape the Core Investment Case for QGEN?
In mid-June 2026, QIAGEN expanded its QIAcuity digital PCR ecosystem with new gene expression assays, a high-multiplex RNA kit, enhanced residual DNA testing, upgraded analysis software and greater automation for life sciences and biopharma labs.
This build-out, including software that standardizes analysis and Hamilton-enabled robotic workflows, points to a stronger push into higher-throughput, regulated applications.
Next, we’ll consider how this expansion of QIAcuity’s automated,...